Form 8-K - Current report:
SEC Accession No. 0001193125-25-193481
Filing Date
2025-09-02
Accepted
2025-09-02 08:55:12
Documents
12
Period of Report
2025-09-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d932295d8k.htm   iXBRL 8-K 26780
  Complete submission text file 0001193125-25-193481.txt   138387

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rgen-20250901.xsd EX-101.SCH 2862
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgen-20250901_lab.xml EX-101.LAB 17232
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgen-20250901_pre.xml EX-101.PRE 10819
15 EXTRACTED XBRL INSTANCE DOCUMENT d932295d8k_htm.xml XML 3521
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 251283175
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)